APTOF (Aptose Biosciences) Debt-to-Revenue : N/A (As of Dec. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Aptose Biosciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Aptose Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.43 Mil. Aptose Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $10.21 Mil. Aptose Biosciences's annualized Revenue for the quarter that ended in Dec. 2024 was $0.00 Mil.

Aptose Biosciences Debt-to-Revenue Historical Data

The historical data trend for Aptose Biosciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Debt-to-Revenue Chart

Aptose Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

Aptose Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Aptose Biosciences's Debt-to-Revenue

For the Biotechnology subindustry, Aptose Biosciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptose Biosciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptose Biosciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aptose Biosciences's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Aptose Biosciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Aptose Biosciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.428	+	10.211)	/	N/A
	=	N/A

Aptose Biosciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.428	+	10.211)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Aptose Biosciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptose Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (OTCPK:APTOF) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

LTI0:Germany LTI0:Germany APS:Canada

Address

251 Consumers Road, Suite 1105, Toronto, ON, CAN, M2J 4R3

Website

https://www.aptose.com

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Executives

William G. Rice	director, officer: Chair, President & CEO	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Bernd R. Seizinger	director	535 BOYLSTON STREET, BOSTON MA 02116
Fletcher Payne	officer: SR VP & Chief Fin. Officer	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Philippe Ledru	officer: Chief Commercial Officer	C/O APTOSE BIOSCIENCES INC., 2511 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Denis R Burger	director	CYTODYN INC., 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Erich Platzer	director
Rafael Bejar	officer: Chief Medical Officer	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Wilson Donald R. Jr.	10 percent owner	540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Holdings, Llc	10 percent owner	540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Commodities, Llc	10 percent owner	540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Warren Whitehead	director	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Gregory K. Chow	officer: Senior VP & CFO	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Jotin Marango	officer: Senior VP, Chief Bus. Officer	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Caroline M Loewy	director	300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Mark D. Vincent	director	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3